Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.50 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848947 | 0.88 | MAPT (0.64) | KDM4EALDH1A1MAPTGAAKMT2A | |
| SCHEMBL1144990 | 0.83 | GPR17 (0.60) | KDM4EGPR17KMT2AMEN1LMNA | |
| SCHEMBL7559900 | 0.80 | KDM4E (0.76) | KDM4EALDH1A1MAPTGAAALOX15 | |
| SCHEMBL7675702 | 0.78 | GAA (0.63) | KDM4EALDH1A1MAPTGAAALOX15 | |
| SCHEMBL4042096 | 0.78 | ALOX15 (0.74) | KDM4EALDH1A1MAPTALOX15 | |
| SCHEMBL7566603 | 0.77 | MAPT (0.83) | KDM4EALDH1A1MAPTGAAALOX15 | |
| SCHEMBL7532157 | 0.77 | MAPT (0.83) | KDM4EALDH1A1MAPTGAAALOX15 | |
| SCHEMBL21801485 | 0.74 | CNR1 (0.68) | KDM4EALDH1A1 | |
| SCHEMBL23254179 | 0.72 | ALOX15 (0.49) | ALOX15GPR17SMN1; SMN2 | |
| SCHEMBL4333071 | 0.72 | GPR17 (0.58) | KDM4EGPR17KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-07-11 | — | — | US | disclosed |
| WO-2002022576-A2 | 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091148-A1 | 3-substituted indole antiproliferative angiogenesis inhibitors | MKI67, FLT4, IDO1 | KDM4E 1608/4885ALDH1A1 98/4885MAPT 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.